New Delhi: Indigenous associate with Microsoft Thursday to leverage Generative AI For him medical industrythe company informed the stock exchange in a filing.
The association aims to help empower global companies life sciences Enterprises expand adoption of enterprise-grade generative AI (GenAI) services, driving faster innovation.
Indegene provides digitally enabled commercialization services for life sciences, biotechnology startups and medical device companies.
“GenAI represents a once-in-a-decade opportunity for life sciences companies to modernize their business processes and reimagine the effectiveness and efficiency of their operations across the value chain. With GenAI, we are working closely with many of our customers to solve specific business problems, with nearly 50 real-world use cases already in an advanced pilot stage,” said Tarun Mathur, CTO at Indegene.
Both companies have committed to developing resources in highly specialized medical and technological tools to co-innovate in generative medicine. Artificial Intelligence Services and workflows across commercial, medical, regulatory and clinical functions.
“With a focus on the right use cases, a responsible and compliant approach to scaling, and shared learnings, we put generative AI to work for our customers,” Tarun added.
Under the agreement, one of the key initiatives is the Content Super App, which uses Azure OpenAI Service. This modular content value chain simplifies content creation and tagging for life sciences companies, offering a comprehensive view of the content creation process. Improve content creation speed, personalize content, and introduce new conversational formats.
It also accelerates creative and video transformation, effectively engaging healthcare professionals, patients and payers.
Generative AI capabilities are also revolutionizing the medical content value chain. Indegene solutions accelerate the creation of key documents such as clinical study reports (CSRs) and protocols by sourcing content from relevant literature. This ensures compliance across clinical and regulatory domains.
“Generative AI is profoundly changing every industry, including life sciences, by offering unprecedented avenues for technological advancements in healthcare. According to a study commissioned by Microsoft and conducted by IDCi, a staggering 79% of healthcare organizations have already adopted AI. This shows that the tangible business value of this transformation is indisputable,” said Alok Lall, COO, Microsoft India and South Asia.
In terms of data management and analysis for clinical trials, Indegene’s solutions, using Microsoft Fabric, improve data ingestion and refinement processes. They also facilitate effortless reporting and ensure governance.
The company added that the agreement results in efficient analytics, regulatory compliance and agility in business operations, providing a competitive advantage in the market. (ANI)
